US EditionPublished • loading... • Updated
Two deaths reported to drug watchdog over potential link to weight-loss jabs
More than 500 adverse reaction reports to GLP-1 drugs include 242 serious cases and six acute pancreatitis incidents, with healthcare professionals submitting 82% of reports.
- The MHRA disclosed two deaths in Northern Ireland reported to the agency, involving a man and a woman aged in their 40s and 60s respectively.
- After a Freedom of Information request, the data show most suspected reactions were registered in 2025 versus 2024, and the MHRA stressed Yellow Card reports indicate suspicion but do not prove causation.
- Breaking down the reports reveals 511 suspected adverse reaction reports from Northern Ireland, with healthcare professionals submitting 82%, and six cases of acute pancreatitis recorded.
- The Coroners Service for Northern Ireland said it could not identify cases linking GLP-1s to death from limited information, and the Department of Health did not respond to queries.
- Northern Ireland NHS access rules limit GLP-1 drugs to type 2 diabetes patients, while about 50 privately paying patients at Portaferry Pharmacy receive Mounjaro costing £200 to £300 monthly amid long-term safety concerns.
Insights by Ground AI
3 Articles
3 Articles
Coverage Details
Total News Sources3
Leaning Left1Leaning Right0Center2Last UpdatedBias Distribution67% Center
Bias Distribution
- 67% of the sources are Center
67% Center
L 33%
C 67%
Factuality
To view factuality data please Upgrade to Premium
